BRAF and lung cancer: To validate the promising combination effects of exarafenib and binimetinib observed in vitro, we evaluated the efficacy of the combination in three patient-derived lung cancer models in vivo, including PDXs: NCI-H1755 (BRAF G469A), CTG-3703 (EGFR exon 19 deletion.; AGK-BRAF PDX), and ST5570 (EGFR exon 19 deletion.; TRIM24-BRAF PDX) (Fig. 6e).